SCHEMBL11936652

SCHEMBL11936652

[11CH3]SC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O

nearest known ligand 0.81

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 10/20 0.81
NAALAD2 Q9Y3Q0 7/20 0.81
RIMKLA Q8IXN7 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11936625 1.00 FOLH1 (0.81) FOLH1NAALAD2RIMKLA
SCHEMBL22636039 1.00 FOLH1 (0.81) FOLH1NAALAD2RIMKLA
SCHEMBL14331633 1.00 FOLH1 (0.81) FOLH1NAALAD2RIMKLA
SCHEMBL11936626 0.91 FOLH1 (0.72) FOLH1NAALAD2RIMKLA
SCHEMBL16580430 0.91 FOLH1 (0.72) FOLH1NAALAD2RIMKLA
SCHEMBL9965336 0.91 FOLH1 (0.72) FOLH1NAALAD2RIMKLA
SCHEMBL12145776 0.90 FOLH1 (1.00) FOLH1NAALAD2RIMKLA
SCHEMBL18161468 0.90 FOLH1 (1.00) FOLH1NAALAD2RIMKLA
SCHEMBL14102890 0.90 FOLH1 (1.00) FOLH1NAALAD2RIMKLA
SCHEMBL14102870 0.90 FOLH1 (1.00) FOLH1NAALAD2RIMKLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4251213-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES ITM Solucin GmbH (DE) 2023-10-04 EP disclosed
EP-4065176-A1 COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER ITM Isotope Technologies Munich SE (DE) 2022-10-05 EP disclosed
WO-2022111800-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES ITM SOLUCIN GMBH (DE) 2022-06-02 WO disclosed
WO-2022112323-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES ITM SOLUCIN GMBH (DE) 2022-06-02 WO disclosed
WO-2022096673-A1 COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER ITM Isotopen Technologien München AG (DE) 2022-05-12 WO disclosed
WO-2022096103-A1 COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER ITM Isotopen Technologien München AG (DE) 2022-05-12 WO disclosed
EP-3965751-A1 PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE ITM Isotope Technologies Munich SE (DE) 2022-03-16 EP disclosed
US-8227634-B2 Imaging agents and methods of imaging NAALADase or PSMA POMPER MARTIN GILBERT (US) 2012-07-24 US disclosed
US-20090117042-A1 Imaging agents and methods of imaging NAALADase or PSMA THE JOHNS HOPKINS UNIVERSITY (US) 2009-05-07 US disclosed
US-7408079-B2 Imaging prostate cancer THE JOHNS HOPKINS UNIVERSITY (US) 2008-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090117042-A1 Imaging agents and methods of imaging NAALADase or PSMA FOLH1, DNPEP, NAALAD2 FOLH1 1/4885NAALAD2 3/4885RIMKLA 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.